FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * DOWNEY BRUCE 2. Issuer Name and Ticker or Trading Symbol MOMENTA PHARMACEUTICALS INC [ MNTA ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET
3. Date of Earliest Transaction (MM/DD/YYYY)
10/1/2020
(Street)
CAMBRIDGE, MA 02142
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/1/2020    D    41844  D  (1) 0  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $18.19  10/1/2020    D        17750    (2) 6/14/2021  Common Stock  17750   (2) 0  D   
Stock Option (Right to Buy)  $14.87  10/1/2020    D        17750    (2) 6/13/2022  Common Stock  17750   (2) 0  D   
Stock Option (Right to Buy)  $14.42  10/1/2020    D        17750    (2) 6/11/2023  Common Stock  17750   (2) 0  D   
Stock Option (Right to Buy)  $13.16  10/1/2020    D        17750    (2) 6/12/2024  Common Stock  17750   (2) 0  D   
Stock Option (Right to Buy)  $22.18  10/1/2020    D        17750    (2) 6/10/2025  Common Stock  17750   (2) 0  D   
Stock Option (Right to Buy)  $10.97  10/1/2020    D        11000    (2) 6/23/2026  Common Stock  11000   (2) 0  D   
Stock Option (Right to Buy)  $17.20  10/1/2020    D        11207    (2) 6/20/2027  Common Stock  11207   (2) 0  D   
Stock Option (Right to Buy)  $22.30  10/1/2020    D        8855    (2) 6/20/2028  Common Stock  8855   (2) 0  D   
Stock Option (Right to Buy)  $12.64  10/1/2020    D        25000    (2) 6/19/2029  Common Stock  25000   (2) 0  D   
Stock Option (Right to Buy)  $38.09  10/1/2020    D        25000    (2) 6/23/2030  Common Stock  25000   (2) 0  D   

Explanation of Responses:
(1)  Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
(2)  Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
DOWNEY BRUCE
C/O MOMENTA PHARMACEUTICALS, INC.
301 BINNEY STREET
CAMBRIDGE, MA 02142
X



Signatures
/s/ R. Mark Chamberlin as attorney in fact 10/1/2020
**Signature of Reporting Person Date
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Momenta Pharmaceuticals Charts.
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Momenta Pharmaceuticals Charts.